SecBot SecBot

RCKT

ROCKET PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001281895 Biotech & Drug Discovery
$2.16 −0.14 (−6.09%)
Nov 16 4:00 PM ET · prev $2.30
Market cap
$266.9M
Micro cap
Consensus
Buy
60% Buy or better · 20 analysts
Median target
$10.00
+363% · range $4.00–15.00
1 year
−28.9%
from $3.04 · Nov 17
30 days
−3.6%
from $2.24
52-week range
$2.16–5.30
at the low
Avg volume 20D
1.65M
shares / day
Short interest
16.24M
≈14.8% of shares · −0.2%
Days to cover
9.1
at average volume
Insider net
−$872.0K
0 buyers · 5 sellers · since Feb 11
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
21
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 0 bearish · 2 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 11/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $872.0K.

  • InstitutionsMIXED

    Q3 2026: 16 added (0 new), 20 trimmed or exited.

  • AnalystsBULLISH

    12 of 20 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −0.2% to 16.24M shares. 9.1 days to cover, ≈14.8% of shares.

  • TrendRANGE

    19% below its 50-day average. New closing low $2.16 on Nov 16.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD13,168,218$34.6M
GEODE CAPITAL MANAGEMENT, LLCTRIM1,716,748$4.5M
MORGAN STANLEYADD1,497,027$3.9M
VANGUARD PORTFOLIO MANAGEMENT LLCNEAR_EXIT1,426,326$3.8M
Aberdeen Group plcDOUBLED1,168,417$3.1M
FMR LLCDOUBLED1,028,743$2.7M
JPMORGAN CHASE & COTRIM763,415$2.0M
Jump Financial, LLCTRIM421,409$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 60% rate it Buy or better
Strong Buy4Buy8Hold7Sell1Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +363%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2026Goldman Sachs
UPGRADE
UPGRADENeutral
Oct 7, 2026Leerink Partners
MAINTAIN
MAINTAINMarket Perform
Oct 7, 2026Wedbush
REITERATE
REITERATEOutperform
Oct 7, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 16, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 16, 2026Needham
UPGRADE
UPGRADEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$872.0K
sold · 5 insiders
DateInsiderTypeValue
Nov 9, 2026
Chaudhuri Sarbani
See Remarks
Nov 9, 2026
SELL$11.3K
Nov 5, 2026
Wilson Martin
General Counsel
Nov 5, 2026
SELL$127.8K
Sep 11, 2026
Wilson Martin
General Counsel
Sep 11, 2026
SELL$256.5K
Aug 18, 2026
Wilson Martin
General Counsel
Aug 18, 2026
SELL$2.1K
Aug 18, 2026
Shah Gaurav
CEO
Aug 18, 2026
SELL$7.8K
Aug 13, 2026
Shah Gaurav
CEO
Aug 13, 2026
SELL$9.6K
Aug 13, 2026
Wilson Martin
General Counsel
Aug 13, 2026
SELL$11.8K
Aug 11, 2026
Stevens Christopher James
Chief Operating Officer
Aug 11, 2026
SELL$128.3K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

9 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
16,242,429
shares short
-0.2%
vs prior settlement
9.1
days to cover
≈14.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Gaurav Shah, an officer and director of Rocket Pharmaceuticals, filed a Form 144 notice of intent to sell 3,020 shares…
144 · Impact 2/10
Nov 13, 2026 SEC
Officer Martin Wilson filed Form 144 notice to sell 4,087 shares of Rocket Pharmaceuticals, valued at approximately…
144 · Impact 2/10
Nov 12, 2026 SEC
Two insiders at Rocket Pharmaceuticals sold a combined $139K in open-market sales within days of the Q3 2026 earnings…
CLUSTER · Impact 3/10
Nov 9, 2026 Insider
Chaudhuri Sarbani sold 4,872 shares
See Remarks @ $2.33 ($11.3K)
Nov 6, 2026 Earnings calendar
RCKT Q3 2026 Earnings After Market Close · 2026-11-06
Nov 5, 2026 Insider
Wilson Martin sold 53,389 shares
General Counsel @ $2.39 ($127.8K)
Sep 30, 2026 Inst.
BlackRock, Inc. · ADD
13,168,218 shares ($34.6M)
Sep 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC · TRIM
1,716,748 shares ($4.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

21 filings · 5 bullish · 1 bearish · 15 neutral
All RCKT filing & press-release reports (21)